Innate Pharma S.A.

LSE:0EVI Stock Report

Market Cap: €180.6m

Innate Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of 0EVI?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders904,4440.981%
Institutions2,165,2912.35%
VC/PE Firms6,389,4066.93%
Public Companies25,648,43327.8%
General Public57,050,22461.9%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 38.08% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
10.7%
Novo Nordisk A/S
9,817,546€19.2m0%no data
9.06%
Sanofi
8,345,387€16.4m0%no data
8.12%
AstraZeneca PLC
7,485,500€14.7m0%no data
6.93%
Bpifrance Participations SA
6,389,406€12.5m0%0.11%
1.01%
CDC Croissance
930,023€1.8m16.7%1.11%
0.53%
Amundi Asset Management SAS
491,602€963.5k0%no data
0.36%
Yannis Morel
332,242€651.2k71.1%no data
0.35%
Saint Olive Gestion
320,000€627.2k0%0.07%
0.26%
Eric Vivier
235,911€462.4k12.2%no data
0.23%
Française Asset Management
209,000€409.6k0%0.22%
0.094%
Odile Belzunce
86,199€168.9k38.5%no data
0.079%
Gilles Brisson
73,059€143.2k0%no data
0.069%
Odile Laurent
63,662€124.8k67.6%no data
0.068%
Exchange Traded Concepts, LLC
62,752€123.0k-50%no data
0.047%
Morgan Stanley, Investment Banking and Brokerage Investments
43,524€85.3k0%no data
0.038%
Frederic Lombard
35,362€69.3k211%no data
0.028%
Claire de Blanquat
25,668€50.3k706%no data
0.027%
Irina Staatz-Granzer
25,100€49.2k0%no data
0.027%
Claresco Finance
25,000€49.0k0%0.02%
0.026%
Dimensional Fund Advisors LP
24,377€47.8k-7.37%no data
0.026%
Citadel Advisors LLC
24,267€47.6k105%no data
0.02%
Henry Wheeler
18,785€36.8k490%no data
0.017%
Millennium Management LLC
15,326€30.0k0%no data
0.0098%
UBS Asset Management AG
9,001€17.6k156%no data
0.0077%
Friedland Gestion
7,100€13.9k0%0.52%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/20 03:48
End of Day Share Price 2025/05/20 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Innate Pharma S.A. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Olga SmolentsevaBryan Garnier & Co
Yigal NochomovitzCitigroup Inc
Michael Thomas CooperEdison Investment Research